Rulings protect generic drugmakers and overturn data-mining ban

06/23/2011 | New York Times (tiered subscription model), The

The Supreme Court handed down a pair of decisions that represent a significant victory for the pharmaceutical industry. A 5-4 ruling shields generic drugmakers from failure-to-warn lawsuits as long as their product labels are identical to those of brand-name drugmakers. A 6-3 decision strikes down a law in Vermont restricting the collection and sale of prescription-drug data.

View Full Article in:

New York Times (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Corporate Life Sciences Lawyer (3-5 years exp)
Ropes & Gray LLP
Boston, MA; San Francisco, CA; Silicon Valley, CA, MA
Director of Accreditation
Meridian Health Plan
Detroit, MI
Health Services Researcher
AARP
Washington, DC
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC